ArticleFrontiers in cardiovascular medicine2026
Preservation of circulatory death donor Rat hearts using hemoglobin-based oxygen carriers for normothermic machine perfusion: enhancing viability and functionality.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ischemia-reperfusion injury (IRI) remains a critical barrier to successful transplantation of donation after circulatory death (DCD) hearts, compromising myocardial viability through oxidative stress, inflammation, and apoptotic pathways. Hemoglobin-based oxygen carriers (HBOCs) are being explored as substitutes for blood and red blood cells (RBCs) in Methods: This study compared the efficacy of HBOC vs. conventional blood or RBC perfusion in attenuating IRI using a rat DCD heart EVHP and transplantation model. Donor hearts were perfused Results: HBOC perfusion significantly reduced myocardial IRI and inflammation, with lower levels of 4-hydroxynonenal (4-HNE) and pro-inflammatory cytokines compared with blood perfusion. Hemodynamic performance, including developed pressure and ±dp/dt, was superior in the HBOC group. In contrast, blood-perfused hearts exhibited elevated potassium and lactate levels, indicating ongoing injury. Post-transplantation analyses demonstrated reduced structural damage and inflammatory infiltration in HBOC-treated hearts. Discussion: These findings indicate that HBOC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.